Nwk Group, Inc. Exelixis, Inc. Transaction History

Nwk Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $41,285 - $58,788	-2,300 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$18.39 - $24.8 $7,356 - $9,920	400 Added 21.05%	2,300 $46,000
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $8,230 - $13,710	-500 Reduced 20.83%	1,900 $45,000
Q1 2020 May 12, 2020	SELL	$14.46 - $21.8 $33,258 - $50,140	-2,300 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $34,845 - $43,447	2,300 New	2,300 $41,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Nwk Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Nwk Group, Inc. with notifications on news.